Home - Products - Others - Other Targets - Tyrosine Kinase Peptide 3 [RRLIEDAE-pY-AARG], Acetylated, Amide, Phosphorylated

Tyrosine Kinase Peptide 3 [RRLIEDAE-pY-AARG], Acetylated, Amide, Phosphorylated

CAS No. ———

Tyrosine Kinase Peptide 3 [RRLIEDAE-pY-AARG], Acetylated, Amide, Phosphorylated( ——— )

Catalog No. M41730 CAS No. ———

Tyrosine Kinase Peptide 3 [RRLIEDAE-pY-AARG], Acetylated, Amide, Phosphorylated

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
25MG Get Quote Get Quote
50MG Get Quote Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    Tyrosine Kinase Peptide 3 [RRLIEDAE-pY-AARG], Acetylated, Amide, Phosphorylated
  • Note
    Research use only, not for human use.
  • Brief Description
    Tyrosine Kinase Peptide 3 [RRLIEDAE-pY-AARG], Acetylated, Amide, Phosphorylated
  • Description
    Tyrosine Kinase Peptide 3 [RRLIEDAE-pY-AARG], Acetylated, Amide, Phosphorylated
  • In Vitro
    ———
  • In Vivo
    ———
  • Synonyms
    ———
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    ———
  • Research Area
    ———
  • Indication
    ———

Chemical Information

  • CAS Number
    ———
  • Formula Weight
    1640.75
  • Molecular Formula
    C66H110N23O24P
  • Purity
    >98% (HPLC)
  • Solubility
    ———
  • SMILES
    ———
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • Cochinchinenin A

    Cochinchinenin A is the material basis for the analgesic effect of Dragons Blood.

  • Handelin

    Handelin has anti-inflammatory activity by inhibiting NF-κB activation and pro-inflammatory cytokine productions.

  • Siplizumab

    Siplizumab (MEDI-507) is a humanized IgG1 monoclonal antibody that targets CD2, selectively depleting effector memory T cells and promoting the relative expansion of alloreactive regulatory T cells in vitro. Siplizumab can be used to treat plaque psoriasis.